Replies to post #42895 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

It’s infuriating!!

—————————————————-

When I got in touch with my contact of Relief about the patent this is what he sent me this was September 2nd or 3rd.... . thought I'd repost it

Relief holds a patent covering potential formulations of RLF-100™ in the United States valid until at least July 2029, with extension opportunities up to five years as well as in the EU and Rest of World (Great Britain, Germany, Turkey, Spain, Switzerland, Netherlands, Denmark, Ireland, Austria, PRC and Mexico) valid until at least 2026, excluding extension opportunities comparable to the U.S. In part to further build the IP portfolio, Relief and AdVita Lifescience GmbH signed a binding term sheet in January 2021 for Relief to acquire all shares of AdVita. Relief will gain access to all AdVita assets including future pending IP rights that may cover RLF-100™ inhaled formulation specifications for the potential application of inhaled aviptadil in the treatment of lung diseases such as ARDS and pulmonary sarcoidosis.

~ Pat dude Pitbull Pat, Y@h00 RLFTF finance conversations